MedTrace Logo

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

NCT02220634 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-01-19

No results posted yet for this study

Summary

The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Regadenoson

Injection for intravenous administration

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Brett E Fenster, MD · National Jewish Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-05-25
Completion
2017-05-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02220634 on ClinicalTrials.gov